AGC Bi­o­log­ics hit with 483 for poor dis­crep­an­cy in­ves­ti­ga­tion prac­tices, qual­i­ty con­trol is­sues at Wash­ing­ton site

CD­MO ACG Bi­o­log­ics re­ceived an FDA 483 let­ter, pub­lished on the FDA web­site this week, not­ing one of its sites failed to con­duct prop­er in­ves­ti­ga­tions in­to dis­crep­an­cies, lack of qual­i­ty con­trol over man­u­fac­tur­ing and lack of as­sur­ance to pre­vent con­t­a­m­i­na­tion.

The 15-page let­ter was writ­ten af­ter a five-day in­spec­tion in Feb­ru­ary 2023 at a site in Both­ell, WA, which is de­signed for mam­malian and mi­cro­bial fer­men­ta­tion man­u­fac­tur­ing, process de­vel­op­ment and R&D.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER